The Hypoxia-Inducible Factor and Tumor Progression Along the Angiogenic Pathway

This publication has 260 references indexed in Scilit:

• The discovery of receptor tyrosine kinases: targets for cancer therapy
  Nature Reviews Cancer, 2004
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
  Nature Reviews Drug Discovery, 2004
• Clinical translation of angiogenesis inhibitors
  Nature Reviews Cancer, 2002
• NATH, a novel gene overexpressed in papillary thyroid carcinomas
  Oncogene, 2002
• Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
  Nature, 2002
• Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation
  The EMBO Journal, 2001
• Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein
  The EMBO Journal, 2000
• The basic-helix–loop–helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors
  Proceedings of the National Academy of Sciences, 1998
• Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
  Nature, 1996
• On the Origin of Cancer Cells
  Science, 1956